Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

857
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
857
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

3.8K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.8K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

14.4K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.4K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Review of Type 1 Diabetes-Reply.

JAMA·2026
Same author

Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect Profile.

Diabetes care·2026
Same author

Accounting for Age-Related Increases in HbA1c More Accurately Quantifies Risk of Type 1 Diabetes Progression in Islet Autoantibody-Positive Adults.

Diabetes care·2026
Same author

Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR).

Diabetes care·2026
Same author

C-Peptide Provides Critical Contextual Insight Into Elevated Glucose Values During Progression to Type 1 Diabetes.

Diabetes care·2026
Same author

Immune Intervention and Beta Cell Replacement Therapies in T1D.

Diabetes technology & therapeutics·2026
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
関連記事をすべて見る

関連する実験動画

Updated: Feb 17, 2026

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

17.0K

1型糖尿病:レビュー

Laura M Jacobsen1, Desmond A Schatz1

  • 1Departments of Pediatrics and Pathology, University of Florida Diabetes Institute, University of Florida College of Medicine, Gainesville.

JAMA
|February 16, 2026
PubMed
まとめ
この要約は機械生成です。

1型糖尿病は,高血糖症とインスリン欠乏症を引き起こす自己免疫疾患であり,世界中で何百万人もの人に影響しています. 自動抗体による早期発見と,継続的なグルコースモニターなどの先進的なインスリン療法により,患者の治療結果が改善されます.

さらに関連する動画

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.3K
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

10.1K

関連する実験動画

Last Updated: Feb 17, 2026

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

17.0K
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.3K
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

10.1K

科学分野:

  • エンドクリノロジー エンドクリノロジー
  • 免疫学 免疫学とは
  • メタボリック障害 メタボリック障害

背景:

  • 1型糖尿病 (T1D) は,胰腺ベータ細胞破壊によって特徴づけられる自己免疫疾患で,インスリン不足と高血糖症を引き起こす.
  • 糖尿病の5〜10%を占め,世界中で何百万もの患者を抱え,微血管およびマクロ血管の重大な合併症を引き起こしています.
  • アンチ-GAD65およびアンチ-ZnT8などの特定の自己抗体の存在は,T1Dの特徴であり,しばしば臨床診断に先立ちます.

研究 の 目的:

  • 1型糖尿病の定義,有病率,診断マーカー,現在の治療戦略など,その主要な側面を要約します.
  • T1Dの早期発見における自己抗体の役割と,先進的なインスリン投与システムの血糖コントロールへの影響を強調する.

主な方法:

  • 1型糖尿病の流行病学,病理生理学,および臨床管理に関する既存のデータの文献レビューと合成.
  • 継続的なグルコースモニターとインスリンポンプを調査したランダム化臨床試験の発見の分析.

主要な成果:

  • 1型糖尿病は,高血糖症と90~95%の患者で小島原抗体の存在によって診断される.
  • インスリンポンプと組み合わせた継続的なグルコースモニタリングは,低血糖症を大幅に減らし,HbA1cレベルを改善します,特にベースラインレベルがより高い個体では.
  • 終身インスリン置換療法は,T1D管理の礎石です.

結論:

  • 1型糖尿病は生涯にわたるインスリン治療を必要とし,先進技術により血糖コントロールが改善され,合併症が軽減されます.
  • 自動抗体検査は,早期診断とT1Dを他の糖尿病タイプから区別するために重要です.
  • T1Dの病原性および新しい治療戦略に関するさらなる研究は,患者のアウトカムを改善するために不可欠です.